company background image
6Y4 logo

Vicore Pharma Holding DB:6Y4 Stock Report

Last Price

€0.72

Market Cap

€189.9m

7D

8.9%

1Y

-42.1%

Updated

02 Jan, 2025

Data

Company Financials +

Vicore Pharma Holding AB (publ)

DB:6Y4 Stock Report

Market Cap: €189.9m

My Notes

Capture your thoughts, links and company narrative

Vicore Pharma Holding AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vicore Pharma Holding
Historical stock prices
Current Share PriceSEK 0.72
52 Week HighSEK 2.01
52 Week LowSEK 0.56
Beta0.66
1 Month Change19.05%
3 Month Change18.66%
1 Year Change-42.09%
3 Year Change-55.47%
5 Year Changen/a
Change since IPO-58.33%

Recent News & Updates

Recent updates

Shareholder Returns

6Y4DE BiotechsDE Market
7D8.9%4.0%0.7%
1Y-42.1%-10.2%8.4%

Return vs Industry: 6Y4 underperformed the German Biotechs industry which returned -11.7% over the past year.

Return vs Market: 6Y4 underperformed the German Market which returned 8.4% over the past year.

Price Volatility

Is 6Y4's price volatile compared to industry and market?
6Y4 volatility
6Y4 Average Weekly Movement7.8%
Biotechs Industry Average Movement7.3%
Market Average Movement4.9%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6Y4's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 6Y4's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200029Ahmed Mousawww.vicorepharma.com

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB (publ) Fundamentals Summary

How do Vicore Pharma Holding's earnings and revenue compare to its market cap?
6Y4 fundamental statistics
Market cap€189.92m
Earnings (TTM)-€17.16m
Revenue (TTM)€9.10m

20.9x

P/S Ratio

-11.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6Y4 income statement (TTM)
RevenueSEK 104.24m
Cost of RevenueSEK 0
Gross ProfitSEK 104.24m
Other ExpensesSEK 300.69m
Earnings-SEK 196.45m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)-0.84
Gross Margin100.00%
Net Profit Margin-188.45%
Debt/Equity Ratio0%

How did 6Y4 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 10:55
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vicore Pharma Holding AB (publ) is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hanseung YooBryan Garnier & Co
Oscar Haffen LammBryan Garnier & Co
Patrik LingDNB Markets